deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT03254446

Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

Sponsor: Iqvia Pty Ltd

Conditions Diabetes Dyslipidemias Hypertension
Interventions Placebo TRC150094
Updated 16 times since 2017 Last updated: Jul 16, 2020 Started: Mar 12, 2018 Primary completion: Apr 30, 2022 Completion: Aug 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes and Dyslipidemias, this trial is ongoing. The trial is conducted by Iqvia Pty Ltd and has accumulated 16 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Sep 2017 – ~Apr 2018 · 7 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Nov 2022 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  5. Oct 2021 — Nov 2022 [monthly]

    Recruiting PHASE3

▶ Show 11 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  2. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  3. Aug 2019 — Aug 2020 [monthly]

    Recruiting PHASE3

  4. Jan 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  5. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  6. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  7. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  8. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  10. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  11. Sep 2017 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Iqvia Pty Ltd
  • Torrent Pharmaceuticals Limited
Data source: Torrent Pharmaceuticals Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angeles City, Philippines , Bangalore, India , Calicut, India , Canoas, Brazil , Dasmariñas, Philippines , Davao City, Philippines , General Luna, Philippines , Hyderabad, India , Jaipur, India , Kochi, India and 10 more locations